Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA(2) in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome

BACKGROUND: Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study w...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyo-Sun, Jung, Chang Hee, Kim, Sung Rae, Jang, Hak Chul, Park, Cheol-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803547/
https://www.ncbi.nlm.nih.gov/pubmed/26754586
http://dx.doi.org/10.3803/EnM.2016.31.1.120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803547/
https://www.ncbi.nlm.nih.gov/pubmed/26754586
http://dx.doi.org/10.3803/EnM.2016.31.1.120

Ejemplares similares